Aspire BioPharma, Inc. (ASBP) Key Metrics
ASBP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $12.3M
- Enterprise value
- $7.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 126.1
- Price / book
- 1.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.17
ASBP key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsASBP valuation Price multiples at each fiscal year-end price.
ASBP returns How much profit the business earns on the capital it uses.
ASBP per-share figures Results divided by the shares outstanding at year-end.
ASBP financial health Debt, liquidity and how easily interest is covered.
ASBP valuation history
ASBP returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ASBP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ASBP cash returned to shareholders
ASBP price vs earnings per share
ASBP key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $236.6M | — | $6.27B | $11.10B | — |
| Enterprise value | $237.0M | — | $6.27B | $11.10B | — |
| Price / book | — | — | 320.0 | 38.4 | — |
| Earnings yield | −10.3% | — | 0.1% | 0.0% | — |
| Free cash flow yield | −2.1% | — | −0.0% | −0.0% | — |
| Shareholder yield (dividends + buybacks) | — | — | 4.5% | — | — |
| Share price at fiscal year-end | $158.28 | — | $13,068.00 | $12,360.00 | — |
| Per share | |||||
| Revenue per share | $0.00 | — | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$16.38 | — | $9.31 | $3.72 | −$0.04 |
| Operating cash flow per share | −$3.29 | — | −$1.36 | −$0.16 | −$0.00 |
| Free cash flow per share | −$3.29 | — | −$1.36 | −$5.61 | −$0.00 |
| Cash per share | $0.67 | — | $0.02 | $0.55 | — |
| Book value per share | −$4.27 | — | $40.83 | $321.74 | −$0.00 |
| Tangible book value per share | −$4.27 | — | $40.83 | $321.74 | −$0.00 |
| Capex per share | $0.00 | — | $0.00 | $5.45 | $0.00 |
| Debt per share | $0.93 | — | $0.03 | $0.03 | $0.35 |
| Shares outstanding | 1.5M | — | 479K | 898K | 683K |
| Change in shares outstanding | — | — | −46.6% | +31.6% | — |
| Returns & profitability | |||||
| Return on equity (ROE) | — | — | 2.9% | 2.3% | — |
| Return on invested capital (ROIC) | — | — | −0.9% | −0.7% | −8.5% |
| Return on assets (ROA) | — | −13.0% | 2.8% | 2.2% | −8.7% |
| Return on tangible assets | — | −885.1% | 22.3% | 1.1% | −8.7% |
| Income quality (OCF / net income) | — | — | −0.15 | −0.04 | — |
| Financial health | |||||
| Total debt | $1.4M | $1.3M | $12,384 | $27,967 | $238,596 |
| Cash & short-term investments | $1.0M | $3,633 | $11,174 | $497,259 | — |
| Net debt | $380,874 | $1.3M | $1,210 | −$469,292 | $238,596 |
| Debt / equity | — | — | 0.00 | 0.00 | — |
| Debt / assets | 1.06 | 8.56 | 0.00 | 0.00 | 0.81 |
| Net debt / EBITDA | — | — | 0.00 | — | — |
| Current ratio | 0.17 | 0.09 | 0.20 | 3.62 | 1.00 |
| Quick ratio | 0.14 | 0.09 | 0.20 | 3.62 | 1.00 |
| Interest coverage | -2.3 | -12.4 | -149.5 | — | — |
| Working capital | −$6.3M | −$1.5M | −$322,105 | $794,429 | −$475 |
| Invested capital | −$6.0M | −$276,889 | $19.6M | $288.6M | $238,121 |
| Tangible asset value | −$6.4M | −$1.5M | $19.6M | $289.1M | −$475 |
| Net current asset value | −$6.4M | −$1.5M | −$322,105 | −$10.0M | −$475 |
| Graham number | — | — | $92.49 | $164.06 | — |
| Graham net-net per share | −$4.39 | — | −$0.82 | −$11.82 | −$0.43 |
| Capital allocation | |||||
| Share buybacks (net) | — | $13.8M | $284.9M | — | — |
| Capex / revenue | 0.0% | — | — | — | — |
| Capex / depreciation | 0.00 | — | 0.00 | — | 0.00 |
| Stock-based compensation / revenue | 227,849.9% | — | — | — | — |
| R&D / revenue | 14,897.0% | — | — | — | — |
| SG&A / revenue | 297,118.0% | — | — | — | — |
| Efficiency | |||||
| Days of inventory on hand | 7,312.7 | — | — | — | — |
| Days payables outstanding | 38,261.9 | — | — | — | — |
| Receivables turnover | — | 0.00 | — | — | — |
| Payables turnover | 0.01 | 0.00 | 0.00 | 0.00 | — |
| Inventory turnover | 0.05 | — | — | — | — |
| Asset turnover | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | $36,503 | — | — | — |
| Average payables | $662,298 | $231,112 | $166,320 | $90,454 | $273 |
| Average inventory | $126,580 | $0 | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ASBP's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ASBP valuation and financial ratios
It ended the year with $1.4 million of debt and $1.0 million in cash and short-term investments, net debt of $0.4 million. The share count rose 118.9% from 683K to 1.5M over 4 years.
See the ASBP income statement, the ASBP chart for price history, or the ASBP stock overview for the latest quote and news.
ASBP key metrics FAQ
How much debt does Aspire BioPharma have?
Aspire BioPharma had total debt of $1.4 million at the end of fiscal 2025.
What is Aspire BioPharma's free cash flow yield?
Aspire BioPharma generated -$4.9 million of free cash flow in fiscal 2025, a free cash flow yield of −2.1% on its market value at year-end ($236.6 million).
What is Aspire BioPharma's current ratio?
Aspire BioPharma's current ratio was 0.17 at the end of fiscal 2025: current assets were 0.17 times current liabilities.